韩国幽门螺杆菌感染一线治疗中伴随、序贯与7天三联疗法比较:随机对照试验研究方案
本研究为在韩国15家医院开展的多中心、研究者盲法随机对照试验,拟比较7天标准三联疗法、10天序贯疗法和10天伴随疗法用于幽门螺杆菌感染一线治疗的疗效与安全性。主要结局为意向治疗人群中的幽门螺杆菌根除率,结果旨在为韩国幽门螺杆菌感染一线治疗方案的选择及指南修订提供关键证据。
要点
- 韩国幽门螺杆菌7天克拉霉素标准三联疗法疗效目前不可接受。
- 研究比较7天标准三联、10天序贯和10天伴随疗法的根除率与安全性。
- 主要结局为意向治疗人群的幽门螺杆菌根除率。
核心结论
- 研究结果将有助于确定韩国幽门螺杆菌感染初次治疗的最佳方案。
- 本研究将产生重要证据,推动幽门螺杆菌感染一线治疗方案相关指南的修订。
研究设计与样本
- 多中心、研究者盲法随机对照试验,从韩国15家医院招募成人幽门螺杆菌感染患者。
- 患者随机接受7天标准三联疗法(兰索拉唑、阿莫西林、克拉霉素)、10天序贯疗法(前5天兰索拉唑和阿莫西林,后5天兰索拉唑、克拉霉素和甲硝唑)或10天伴随疗法(兰索拉唑、阿莫西林、克拉霉素和甲硝唑)。
- 主要结局为意向治疗人群中的幽门螺杆菌根除率。
- 试验注册于韩国Clinical Research Information Service(CRIS),注册号KCT0001980,注册日期2016年7月25日。
关键数值与推荐
- 多数国际指南推荐质子泵抑制剂、克拉霉素和阿莫西林/甲硝唑组成的三联方案,疗程至少7天,用于根除幽门螺杆菌。
- 韩国7天克拉霉素标准三联疗法治疗幽门螺杆菌感染的疗效目前不可接受。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most international guidelines recommend triple-therapy regimens consisting of a proton pump inhibitor, clarithromycin, and amoxicillin/metronidazole for at least 7 days for the eradication of Helicobacter pylori. However, the efficacy of 7-day clarithromycin-based standard triple therapy for H. pylori infection is currently unacceptable in Korea. In this study, we will compare the efficacy and safety of 7-day standard triple therapy, 10-day sequential therapy, and 10-day concomitant therapy for the first-line treatment of H. pylori infection in Korea. METHODS/DESIGN: In this multicenter, investigator-blinded, randomized trial we are recruiting adult patients with H. pylori infection from 15 hospitals in Korea to determine whether sequential or concomitant treatment is superior to standard triple therapy. Patients are randomly assigned to receive either standard triple therapy (lansoprazole, amoxicillin, and clarithromycin) for 7 days, or sequential treatment (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin, and metronidazole for another 5 days) for 10 days, or concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole) for 10 days. The primary outcome is the rate of H. pylori eradication in the intention-to-treat population. DISCUSSION: The results of this study will be crucial for determining the optimal regimen for the primary treatment of H. pylori infection in Korea. This study will produce vital evidence that will lead to revisions to guidelines concerning first-line treatment regimens for H. pylori infection. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), Republic of Korea, KCT0001980 . Registered on 25 July 2016.
引用
- Lee H, Kim BJ, Kim SG, et al. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29149904. doi:10.1186/s13063-017-2281-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。